In November 2025, the Trump administration announced pricing agreements with Eli Lilly and Novo Nordisk that dropped brand GLP-1 drug prices by 68-74%. Ozempic went from $1,000/month to $350 on TrumpRx. Zepbound dropped from $1,086 to $346. The GLP-1 pill Foundayo starts at $149/month. For men who have been buying research-grade semaglutide and tirzepatide because brand pricing was absurd, these numbers force an honest recalculation.
⚡ Key Takeaway
TrumpRx brand GLP-1 pricing: Ozempic/Wegovy ~$350/month, Zepbound ~$346/month, Foundayo (orforglipron) ~$149/month. Research-grade semaglutide runs $50-150/month depending on vendor and concentration. The price gap has narrowed dramatically, but the access and quality calculus depends on your specific situation.
The New Pricing Landscape
TrumpRx is a government-operated platform that connects consumers to manufacturer discount programs. It does not sell drugs directly — it routes you to Novo Nordisk’s or Eli Lilly’s direct-to-consumer platforms at negotiated prices. The key numbers:
Novo Nordisk products on TrumpRx: Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight loss) both priced at approximately $350/month, down from list prices of $1,000 and $1,350 respectively.
Eli Lilly products on TrumpRx: Zepbound (tirzepatide for weight loss) at approximately $346/month, down from $1,086 list. Foundayo (orforglipron, the oral GLP-1) at $149/month for the starting dose.
Medicare beneficiaries: $50/month copay for GLP-1 drugs for obesity through a new CMMI demonstration. This is the first time Medicare has covered weight-loss drugs.
The administration projects the average TrumpRx GLP-1 price will trend from $350/month to approximately $245/month over the next two years as competition and volume increase.
The Research-Grade Economics
Research-grade semaglutide from reputable vendors with third-party COAs typically runs $50-150/month depending on concentration, reconstitution volume, and dosing. Research-grade tirzepatide is similar. These prices have not changed significantly in response to the TrumpRx announcement because the research market and the pharmaceutical market serve different audiences through different regulatory channels.
The cost math has shifted from a 10:1 ratio (brand at $1,000 vs research at $100) to roughly a 2.5:1 ratio (brand at $350 vs research at $100-150). That compressed ratio changes the decision calculus for a lot of men who were in the research market primarily for economic reasons.
What You Get for the Premium
Brand GLP-1 drugs through TrumpRx offer several things research-grade peptides cannot: verified pharmaceutical-grade purity with FDA manufacturing oversight, standardized dosing with pre-filled injection pens (no reconstitution), physician supervision and prescription, insurance compatibility for some plans, and legal clarity — you are using an FDA-approved drug for its approved indication.
Research-grade GLP-1 peptides offer: lower cost, no prescription requirement, no waiting room or telehealth appointments, and the flexibility to dose at non-standard levels (relevant for microdosing protocols). The trade-offs are uncertain purity without independent COA verification, reconstitution responsibility, and legal ambiguity.
The Honest Decision Framework
Switch to brand if: The price gap no longer justifies the quality uncertainty. You have insurance that now covers GLP-1s. You want physician oversight for dosing and monitoring. You prefer the convenience of pre-filled pens. You want unambiguous legal standing.
Stay research-grade if: The remaining price gap matters to your budget. You are microdosing at levels below what standard prescriptions provide. You have established a reliable vendor with consistent COA quality. You do not want the prescription infrastructure (appointments, refills, prior authorizations).
Consider Foundayo specifically if: You want the simplest possible protocol — an oral GLP-1 pill at $149/month with no injections, no reconstitution, no food/water timing restrictions. The 12.4% weight loss at 72 weeks is lower than injectable options, but the convenience factor is unmatched. For men who want moderate appetite management without the injection commitment, this is a genuinely new option.